The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
The branding initiative coincides with the company's expansion.
The category is expected to cross Rs 38,400 crore by 2020.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
Financial numbers can sometimes paint a rosy picture because of changes in the accounting policy or a one-time income.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances